Ulcerative colitis trials recruiting in Washington
All Ulcerative colitis trials nationally
23
Recruiting in Washington
6
Cities with sites
Cities in Washington
Tacoma 15Seattle 9Bellevue 5Vancouver 3Silverdale 1Spokane 1
Recruiting trials in Washington
- A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD)
- A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
- A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease
- A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis
- A Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With Moderate to Severe Active Ulcerative Colitis
- A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis
- A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis
- A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis
- A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC)
- A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting
- A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease
- A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Ulcerative Colitis
- A Study to Test Whether BI 3032950 Helps People With Ulcerative Colitis
- An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
- An Observational Study of Etrasimod in Adult Patients With Moderate to Severe Ulcerative Colitis
- Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)
- Familial Inflammatory Bowel Disease Early Risk
- LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:
- LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis
- Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
- Seattle Spatial Transcriptomic Research in Inflammatory Bowel Disease Evaluation (STRIDE)
- Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis
- Study of Tilpisertib Fosmecarbil in Participants With Moderately to Severely Active Ulcerative Colitis